Brentuximab vedotin
Monoclonal Antibody
DB08870
Approved Indication
Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
1
Targets
0
Resistance Mutations
1
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network.
Details
DrugBank ID
DB08870 ↗
Approval Date
2011-08-25
Molecular Weight
— g/mol
Drug Class
Monoclonal Antibody
ATC Codes
L01XC12
Synonyms
cAC10-vcMMAE
ChEMBL
CHEMBL1742994 ↗
Drug References (DrugBank)